Evaluation of hemostatic balance in blood from patients with polycythemia vera by means of thromboelastography: The effect of isovolemic erythrocytapheresis

References

• Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937–951
   PubMed Web of Science ®Google Scholar
• Schafer A. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107: 4214–4222
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148
   PubMed Web of Science ®Google Scholar
• Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Guglielmelli P. Advances in understanding and management of polycythemia vera. Curr Opin Oncol 2010; 22: 636–641
   PubMed Web of Science ®Google Scholar
• Landolfi R, Cipriani M, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006; 19: 617–633
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523–530
   PubMed Web of Science ®Google Scholar
• Falanga A, Barbui T, Rickles F. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost 2008; 34: 204–210
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Barbui T, Smith C. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils. Semin Hematol 2005; 42: 239–247
   PubMed Web of Science ®Google Scholar
• Duchemin J, Ugo V, Ianotto J, Lecucq L, Mercier B, Abgrall J. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 2010; 126: 238–242
   PubMed Web of Science ®Google Scholar
• Marchetti M, Castoldi E, Spronk H, van Oerle R, Balducci D, Barbui T, Rosing J, ten Cate H, Falanga A. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112: 4061–4068
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T. V617F JAK-2 mutation in patients with essential thrombocythemia: Relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35: 702–711
   PubMed Web of Science ®Google Scholar
• Kaboth U, Rumpf K, Liersch T, Vehmeyer K, Krieter D, Kaboth W. Advantages of isovolemic large-volume erythrocytapheresis as a rapidly effective and long-lasting treatment modality for red blood cell depletion in patients with polycythemia vera. Ther Apher 1997; 1: 131–134
   PubMedGoogle Scholar
• Ng K, Lam C, Chan L. In vivo effect of haemodilution with saline on coagulation: A randomized controlled trial. Br J Anaesth 2002; 88: 475–480
   PubMed Web of Science ®Google Scholar
• Nielsen V, Lyerly Rr, Gurley W. The effect of dilution on plasma coagulation kinetics determined by thrombelastography is dependent on antithrombin activity and mode of activation. Anesth Analg 2004; 99: 1587–1592
   PubMed Web of Science ®Google Scholar
• Ruttmann T, James M, Viljoen J. Haemodilution induces a hypercoagulable state. Br J Anaesth 1996; 76: 412–414
   PubMed Web of Science ®Google Scholar
• Reikvam H, Steien E, Hauge B, Liseth K, Hagen KG, Størkson R, Hervig T. Thrombelastography. Transfus Apher Sci 2009; 40: 119–123
   PubMed Web of Science ®Google Scholar
• Luddington R. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81–90
   PubMedGoogle Scholar
• Bowbrick V, Mikhailidis D, Stansby G. Influence of platelet count and activity on thromboelastography parameters. Platelets 2003; 14: 219–224
   PubMed Web of Science ®Google Scholar
• Ciborowski M, Tomasiak M, Rusak T, Winnicka K, Dobrzycki S. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Blood Coagul Fibrinolysis 2008; 19: 557–567
   PubMed Web of Science ®Google Scholar
• Zambruni A, Thalheimer U, Leandro G, Perry D, Burroughs A. Thromboelastography with citrated blood: Comparability with native blood, stability of citrate storage and effect of repeated sampling. Blood Coagul Fibrinolysis 2004; 15: 103–107
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372–380
   PubMed Web of Science ®Google Scholar
• Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551–558
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate-induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010; 160: 346–354
   PubMed Web of Science ®Google Scholar
• Raschka C, Koch HJ. [Pharmacokinetics after oral and intravenous administration of D,L-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. Therapie 2001; 56: 669–674
   PubMed Web of Science ®Google Scholar
• Spivak J. Polycythemia vera: Myths, mechanisms, and management. Blood 2002; 100: 4272–4290
   PubMed Web of Science ®Google Scholar
• Hagberg I, Akkok C, Lyberg T, Kjeldsen-Kragh J. Apheresis-induced platelet activation: Comparison of three types of cell separators. Transfusion 2000; 40: 182–192
   PubMed Web of Science ®Google Scholar
• Procházková R, Andrýs C, Hubácková L, Krejsek J. Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis. Transfus Apher Sci 2007; 37: 115–123
   PubMed Web of Science ®Google Scholar
• Bolliger D, Görlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010; 113: 1205–1219
   PubMed Web of Science ®Google Scholar
• Amitrano L, Guardascione M, Ames P, Margaglione M, Antinolfi I, Iannaccone L, Annunziata M, Ferrara F, Brancaccio V, Balzano A. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: Relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003; 72: 75–81
   PubMed Web of Science ®Google Scholar
• Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996; 52: 14–20
   PubMed Web of Science ®Google Scholar
• Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Effects of progressive blood loss on coagulation as measured by thrombelastography. Anesth Analg 1987; 66: 856–863
   PubMed Web of Science ®Google Scholar